.jpg)
13 hours ago
1
Article content
TORONTO — A groundbreaking first-in-human trial has revealed the potential of the PeriPulse® Nerve Stimulation System, a wearable temporary nerve stimulator, in enabling electrical stimulation therapy for the regeneration of acutely injured peripheral nerves. In a study published in Bioelectronic Medicine, results showed a significant and sustained improvement in sensation, with 87.5% of treated patients demonstrating clinically meaningful gains 6 months after injury compared to pre-surgery. This highlights the potential of electrical stimulation therapy to drive substantial functional recovery.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
Article content
Treating peripheral nerve injuries remains challenging, particularly in acute trauma scenarios. Surgery, the current standard of care, often results in slow and incomplete recovery, creating substantial burdens for patients and healthcare systems. Epineuron’s novel PeriPulse® system provides a simple workflow to improve patient outcomes without prolonging operating room time. “This publication is an important milestone for Epineuron and a testament to our vision for the future of improving nerve regeneration. The utility of our efficient approach to deploying therapy was validated and we look forward to helping patients recover following nerve surgery,” said Dr. Mike Willand, PhD, Co-Founder and CTO at Epineuron.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
The system demonstrated a high degree of patient tolerance and safety, underscoring its potential for widespread adoption. The findings offer new hope for patients and provides surgeons the prospect of delivering needed treatment. The study results have paved the way for REGAIN™, the largest multinational medical device trial for nerve regeneration, currently underway across Canada and the US, which is designed to support the company’s FDA approval.
Article content
“Better nerve regeneration is game changing for patients,” said Dr. James Bain, MD, MSc, Professor of Plastic Surgery, McMaster University and corresponding author of the study. “The novel system provides a simple and effective way to deliver electrical stimulation therapy that does not impact my workflow and prolong my surgeries. This system and approach have the potential to significantly improve outcomes for patients with peripheral nerve injuries.”
Article content
About Epineuron
Article content
Epineuron is a nerve care company dedicated to advancing bioelectronic solutions for the repair and treatment of damaged nerves. Its flagship technology, PeriPulse®, is Health Canada approved and designated an FDA Breakthrough Device. It uses electrical stimulation to accelerate the recovery of injured peripheral nerves with a seamless perioperative workflow.
Article content
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Dr. Mike Willand, PhD, PEng
[email protected]
Article content
Article content
English (US)